

Research paper**The Effect of Leaf Ethanol Extract of  
*Coccinia Grandis* Lin in glucose and  
cholesterol lowering activity**

Md. Mamun Al-Amin<sup>1\*</sup>, Mir Muhammad Nasir Uddin<sup>1</sup>, Ashfique Rizwan<sup>2</sup>,  
Md. Siddiquil Islam<sup>3</sup>

<sup>1</sup>Department of Pharmacy, North South University, Bashundhara, Dhaka 1229, Bangladesh

<sup>2</sup>Department of Pharmacy, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh

<sup>3</sup>Department of Pharmacy, Manarat International University, Dhaka 1212, Bangladesh

---

**ABSTRACT**

**Aims:** To investigate the effect of the leaf extract of *Coccinia Grandis* Lin (Cucurbitaceae) in glucose and cholesterol lowering activity in animal models.

**Study design:** Extraction, glucose and cholesterol lowering activity evaluation.

**Place and Duration of Study:** Department of Pharmacy, North South University, Dhaka between June 2012 and December 2013.

**Methodology:** The glucose and cholesterol lowering effect of the ethanol leaf extract of *Coccinia Grandis* Lin (Cucurbitaceae) was evaluated using the alloxan monohydrate induced diabetic rat and compared the activity with control and Glibenclamide. Graded doses of the ethanol extract and Glibenclamide were administered to normal and experimental diabetic rats for 10 days.

**Results:** Phytochemical screening showed the presence of alkaloids, flavonoids, saponins, cardenolides and polyphenols in significant amounts. In the alloxan induced diabetic rat model, *C. grandis* at 2 ml significantly ( $p < 0.05$ ) lowered fasting blood glucose levels. The extract (2ml) also produced significant total cholesterol lowering ( $p < 0.05$ ) and HDL increasing ( $p < 0.05$ ) effects at 2ml. In addition, body weight was significantly ( $p < 0.05$ ) increased in the *C. grandis* group.

**Conclusion:** These results suggest that the aqueous leaf extract of *C. grandis* possesses significant glucose and cholesterol lowering activity in animal models, thus supporting the usage of the plant in traditional medicine as an anti-diabetic medication.

**Keywords:** Antidiabetic activity, Glibenclamide, *Coccinia grandis*.

**1. INTRODUCTION**

High glucose and cholesterol level are known independent factors and accelerate the risk of coronary heart disease [1,2]. The intolerance of glucose metabolism is linked with the cholesterol. Moreover, the actions of insulin and cholesterol metabolism are interrelated [3].

29 Extensive research work has been conducted so far for the management of heart disease  
30 and associated complications like diabetes. The search for new chemical entities from plant  
31 source is a common practice in south Asian research. A large number of medicinal plants  
32 have been studied over the years for lowering the blood glucose [4,5] and cholesterol [6]  
33 level.

34 Phytochemicals produced by the plants like *Coccinia grandis* is used in the treatment of  
35 diabetes in Asian countries as Ayurvedic remedies. *Coccinia grandis* is also known as its  
36 synonyms *Coccinia indica* and *Coccinia cordifolia* [5]. *C. grandis* Linn is a medicinal plant  
37 under the family: Cucurbitacea. Phytochemical screening of *C. grandis* reported the  
38 presence of triterpenoides [7], carotenoides [8], flavonoids, [9], alkaloids [10] and fatty acids  
39 [11].

40 Extract of *C. grandis* leaves shows blood glucose lowering activity. Decreased phagocyte  
41 activities of macro-phages in alloxan-induced diabetic animal indicate its activity in reducing  
42 lipid peroxidation. Kumar and his colleagues in 1993 reported that pectin of *C. indica* is  
43 responsible for providing this hypoglycemic action [12]. Human trials [5,13] confirm the  
44 glucose lowering action of *C. grandis* [13]. In a double blind clinical trial 61 healthy  
45 volunteers were taken 20 g of leaves of *C. grandis* and 61 healthy volunteers were taken  
46 placebo meals in their dinner. All of the volunteers were maintained a 10-hour fasting period.  
47 The authors reported that low postprandial blood glucose levels in the experimental group  
48 than the control groups in both 1 hour and 2 hour postprandial period [5]. *C. grandis* reduces  
49 phosphorylase activity, increases liver glycogen and thus lower the blood glucose level [12].  
50 Moreover, glucose lowering effect is also achieved by inhibiting key gluconeogenic enzyme,  
51 glucose-6-phosphatase in animal model [14].

52 Singh G et al., in 2007 reported that polyphenols of *C. grandis* lowers the plasma lipid level  
53 followed by a beneficial effect on HDL and its ratio with total cholesterol, in dyslipidemic  
54 hamster model [15]. Previous research also stated that the action of polyphenols was  
55 mediated through peroxisome proliferators activated receptor- $\alpha$  (PPAR $\alpha$ ), by catabolizing  
56 triglycerides and improving HDLC/TC ratio for the maintenance of lipid-glucose homeostasis  
57 in hamster model [16,17].

58 Aims of the present study

59 Many research works has been carried out so far to investigate the antidiabetic activity of  
60 *Coccinia grandis*. However, there are very limited research has been carried out to  
61 investigate the ethanol extract of the plant *C. grandis* in diabetic animal model. Hence, we  
62 aimed to explore the glucose and cholesterol lowering property of *C. grandis* and investigate  
63 the induced weight changes. Alloxan is used in our current study to induce diabetes in  
64 animal model. In rodent model alloxan selectively destroys pancreatic beta cell which in turn  
65 shut down the production of insulin. In the presence of thiols, alloxan generates reactive  
66 oxygen species (ROS) which in turn initiate toxic action in the beta cell by free radical  
67 formation.

68 Hypothesis

69 We hypothesized that since *Coccinia grandis* will be able to lower blood glucose level, its  
70 leave extract might have a distinct mechanism to provide glucose and cholesterol lowering  
71 activity in the animal model. We also thought that *C. grandis* will not affect the total body  
72 weight after administering the extract in the animal model. We also thought that, *C. grandis*  
73 might enhance HDL level in the plasma.

74

## 75 2. MATERIAL AND METHODS

76

### 77 2.1 Plant Material

78 The leaves of *Coccinia grandis* were collected in December from Jessore city in Bangladesh  
79 and authenticated by Bangladesh National Herbarium. The leaves were initially dried under  
80 shade.

### 81 2.2 Preparation of extract

82 The extract was prepared at the rate of 1g/5ml of solvent in a 250mL flasks with mild  
83 shaking. The flasks were closed with cotton plug and aluminum foil with mild shaking at 48  
84 hours at room temperature, filtered through what man filter paper No.1 and then  
85 concentrated by using a rotary evaporator at low temperature (40-50°C). The extracts were  
86 preserved in airtight containers and kept at 4°C until further use.

### 87 2.3 Phytochemical Screening

88 Qualitative phytochemical tests for the identification of alkaloids, flavonoids, steroids,  
89 glycosides, saponins, tannin and terpenoids were carried out for all the extracts by the  
90 method described by Harborne and Sazada [18,19]. Phytochemical screening of the extract  
91 was performed using the following reagents and chemicals: Alkaloids with Wagner reagent,  
92 flavonoids with the use of conc. HCl, tannins with 5%, and saponins with ability to produce  
93 suds. Gum was tested using Molish reagents and concentrated sulfuric acid, steroids with  
94 sulfuric acid, reducing sugar with the use  $\alpha$ -naphthol and sulfuric acid and terpenoids with  
95 chloroform and concentrated HCl.

### 96 2.4 Test animals

97 Test animals were obtained from International Cholera and Dysentery Disease Research, in  
98 Bangladesh (icddr, b). Albino rats (wistar strain) of either sex weighing 150 - 200 g bred in  
99 Pharmacology research Lab at Jahangirnagar University in Bangladesh were used for the  
100 study. They were individually housed in polypropylene cages in well-ventilated rooms, under  
101 hygienic conditions. Animals were given water and fed with rat pellet feed. Experimental  
102 protocol was approved by Institutional Ethics Committee of the Department of Pharmacy,  
103 North South University (approval no. NSU/DP/12/11). Animals were handled in accordance  
104 with international principles guiding the use and handling of experimental animals (United  
105 States National Institutes for Health Publication, 1985).

### 106 2.5 Induction of diabetes and treatment

107 The solution of Alloxan monohydrate (10 mg/ml) was prepared in ice-cold citrate buffer 0.1 M  
108 pH 4.5 and kept in ice. Then the solution was administered intraperitoneally to the animals  
109 within 5 minutes at a dose of 50 mg/kg body weight. After 48 hours of administration,  
110 diabetic model rats having glycosuria and hyperglycemia were taken for the experiment.  
111 Rats weighing 150 – 160 g fasted over night were used for induction of diabetes. Rats were  
112 divided into two sets; diabetic and non-diabetic. Group I received normal diet and served as  
113 normal control. Group II consists of alloxan-induced rats receiving normal diet and serving as  
114 diabetic control. Group III consists of alloxan- induced rats receiving Glibenclamide  
115 (synthetic antidiabetic drug) at 0.5 mg/kg body weight once a day orally for 10 days. Group  
116 IV consists of alloxan-induced rats receiving *C. grandis* Linn (2ml) once a day orally for 10  
117 days. Group V consists of normal rats receiving *C. grandis* (2 ml) once a day orally for 10

118 days. Blood samples were collected through the tail vein just prior to and on day 10 after  
 119 drug administration. The blood glucose and cholesterol levels were analyzed for all the  
 120 samples.

121 2.6 Statistical Analysis

122 The results of statistical analysis for animal experiment were expressed as mean  $\pm$  SEM and  
 123 were evaluated by ANOVA followed by Dunnet’s multiple comparisons. The results obtained  
 124 were compared with the vehicle control group. The  $p < 0.05$ , 0.001 were considered to be  
 125 statistically significant. All the statistical tests were carried out using SPSS statistical  
 126 software.

127 **3. RESULTS AND DISCUSSION**

128  
 129 Phytochemical screening of the extract of *Coccinia grandis* revealed the presence of various  
 130 bioactive components of which alkaloid, cardenolides, flavonoides and polyphenols were the  
 131 most prominent. The result of phytochemical test is summarized in the Table 1.

132 **Table 1:** Phytochemical investigation of ethanol extract *C. grandis*.

133

Test	Alkaloids	Cardenolides	Flavonoids	Terpenoids	Saponins	Polyphenols
Observation	+	++	+++	+	+++	+

134 +++ indicates presence in high concentrations; ++ indicates presence in moderate concentrations;  
 135 ‘+’ indicates presence in trace concentration; ‘-’ indicates absence  
 136

137 Blood glucose levels were measured for all the animals. The blood glucose level were 119.6  
 138 mg/dl in control group, 248.1 mg/dl in alloxan induced diabetic animal, 101.11 mg/dl in  
 139 glibenclamide treated diabetic groups, 108.42 mg/dl in *C. grandis* treated diabetic group. The  
 140 differences were significant between control and diabetic control, diabetic control and  
 141 glibenclamide treated diabetic group, diabetic control and *C. grandis* treated diabetic group  
 142 (Table 2). Total Cholesterol levels were also determined for all animals. The blood  
 143 cholesterol level were 124.7 mg/dl, 238.1 mg/dl, 106.08 mg/dl, 111.78 mg/dl for control  
 144 group, alloxan induced diabetic animal, glibenclamide treated diabetic groups and *C. grandis*  
 145 treated diabetic group respectively. The differences were significant between control and  
 146 diabetic control, diabetic control and glibenclamide treated diabetic groups, diabetic control  
 147 and *C. grandis* treated diabetic groups (Table 2). The HDL level were 42.23 mg/dl in control  
 148 group, 37.51 mg/dl in alloxan induced diabetic animal, 38.81 mg/dl in glibenclamide treated  
 149 diabetic groups, 49.67 mg/dl in *C. grandis* treated diabetic group.


150 **Table 2.** Glucose and cholesterol level in serum between control and experimental animal groups.

Parameter (mg/dl)	Control	Diabetic Control	Diabetic Glibenclamide (1ml) <sup>+</sup>	Diabetic + <i>C. Grandis</i> Extract treated (2ml)
Glucose	119.6 $\pm$ 1.4	248.1 $\pm$ 1.6***	101.11 $\pm$ 1.7**	108.42 $\pm$ 1.2*
Total Cholesterol	124.7 $\pm$ 1.5	238.1 $\pm$ 1.2***	106.08 $\pm$ 1.8**	111.78 $\pm$ 11.2*
HDL	42.23 $\pm$ 2.7	37.51 $\pm$ 2.87*	38.81 $\pm$ 5.91*	49.67*

151 Data were represented as the mean  $\pm$  SEM. Data were analyzed by one way ANOVA followed by  
 152 Dunnet's multiple comparison. The criterion for statistical significance was \*\*\* $p < 0.001$ , \*\* $p < 0.01$   
 153 and \* $p < 0.05$ .

154  
 155

**Figure 1.** Effect of *C. Grandis* extracts on the body weight of diabetic rats.



156 Data were represented as the mean  $\pm$  SEM. Data were analyzed by one way ANOVA followed by  
 157 Dunnet's multiple comparison. The criterion for statistical significance was  $p < 0.05$ .

158  
 159  
 160  
 161  
 162  
 163

Total body weights were also measured for all animals on day zero (just before administration of extract), day 5 and day 10. Average body weight was different before the administration of drug among the animal groups. Interestingly the body weight was increased for the diabetic animals that are treated with *C. grandis*. Average body weights of other animal groups were remaining unchanged (Figure 1).

164 Experimental result showed that ethanol extracts of *C. grandis* lowers the serum glucose and  
 165 total cholesterol level in the alloxan induced diabetic rats. Moreover, HDI level was also  
 166 raised by the ethanol extract of *C. grandis*. Similar results were observed for the diabetic rats  
 167 with Glibenclamide. Reduced Blood glucose levels were consistent over long term treatment  
 168 with *C. grandis* extracts on alloxan-induced diabetes rats. Our findings indicates that ethanol  
 169 extract of *C. grandis* improve the blood glucose tolerance. The lowering of blood glucose  
 170 level may achieved by the increased glycogen synthesis and suppression of glucose 6-  
 171 phosphatase enzyme. Other mechanisms might also be involved for glucose lowering action.  
 172 Mechanisms including the reduced sugar absorption from the gut, rising of insulin production  
 173 from the pancreas, reduction of insulin release from the liver or reduction of glycogen  
 174 breakdown, increase the conversion of glucose to other substance such as fatty acid or  
 175 amino acid can also be involved in reducing the glucose level in the blood. Previous  
 176 research [13,14] findings are consistent with our present findings. Therefore, *C. grandis* can  
 177 be recommended for diabetic patients.

178 In the present study ethanol extract of *C. grandis* was able to reduce the cholesterol level  
 179 during the 10 days treatment period. Singh G et al., in 2007 isolate polyphenol from *C.*  
 180 *grandis* leaf by ethanol extract. The authors reported that polyphenol might be responsible for  
 181 cholesterol-lowering effects [20]. Krishnakumari, S. et al., in 2011 investigate the activity of

182 methanol extract on lipid profile in streptozotocin induced diabetic rats. The authors reported  
183 that lipid profile increased in diabetic group, and after the treatment with the methanol extract  
184 the lipid profiles back to the normal level [21].

185 Body weight of the diabetic animals was increased after the administration of ethanol extract  
186 of *C. grandis*. This weight enhancing effect was not found in glibenclamide group. The  
187 mechanism of body weight changes possibly due to the deposition of fatty substance in the  
188 body. Further research is needed to explore the root cause of increased body weight.  
189 Further investigations of its activity against a blood glucose tolerance, specific lipids such as  
190 LDL, VLDL, HDL and purification of its chemical constituents, and toxicological investigations  
191 of the plant extracts should be carried out with a view to developing novel drugs for human  
192 consumption.

#### 193 **4. CONCLUSION**

194

195 In conclusion, ethanol extract of *Coccinia grandis* showed blood glucose lowering effect in  
196 diabetic rodent model after oral administration. Thus, the uses of this plant extract as a  
197 traditional medicine in the treatment of diabetes is validated. Further studies should be  
198 conducted to isolate the lead compound(s) that is/are responsible for providing this action.  
199

200

201

#### 201 **COMPETING INTERESTS**

202

203 No competing interests exist.

204

#### 205 **AUTHORS' CONTRIBUTIONS**

206

207 Author MMNU designed the study, wrote the protocol and wrote the first draft of the  
208 manuscript. Author MMAA performed the statistical analysis of the study and finalize the  
209 manuscript. Author AR managed the literature searches. All authors read and approved the  
210 final manuscript.

211

#### 212 **CONSENT (WHERE EVER APPLICABLE)**

213

214 This section is not applicable in our paper.

215

#### 216 **ETHICAL APPROVAL (WHERE EVER APPLICABLE)**

217

218 Experimental protocol was approved by Institutional Ethics Committee of the Department of  
219 Pharmacy, North South University (approval no. NSU/DP/12/11). Animals were handled in  
220 accordance with international principles guiding the use and handling of experimental  
221 animals (United States National Institutes for Health Publication, 1985).

222

#### 223 **REFERENCES**

224

225 1. Cohen, H.W., Hailpern, S.M. & Alderman, M.H. Glucose-cholesterol interaction  
226 magnifies coronary heart disease risk for hypertensive patients. *Hypertension*,  
227 2004a;43, 983-7.

228 2. Cohen, H.W., Sloop, G.D. & Study, P. Glucose interaction magnifies atherosclerotic  
229 risk from cholesterol. Findings from the PDAY Study. *Atherosclerosis*, 2004b;172,  
230 115-20.

- 231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281
3. Hallikainen, M., Toppinen, L., Mykkanen, H., Agren, J.J., Laaksonen, D.E., Miettinen, T.A., Niskanen, L., Poutanen, K.S. & Gylling, H. Interaction between cholesterol and glucose metabolism during dietary carbohydrate modification in subjects with the metabolic syndrome. 2006; *Am J Clin Nutr*, 84, 1385-92.
  4. Bailey, C.J. & C. Day, Traditional Plant Medicines as Treatments for Diabetes. *Diabetes Care*. 1989;12(8):553-564
  5. Munasinghe, M., Abeysena, C., Yaddhige, I.S., Vidanapathirana, T. & Piyumal, K.P.B. Blood Sugar Lowering Effect of *Coccinia grandis* (L.) J. Voigt: Path for a New Drug for Diabetes Mellitus. *Exp Diabetes Res*, 2011; 978762.
  6. Doornbos, A.M., Meynen, E.M., Duchateau, G.S., Van Der Knaap, H.C. & Trautwein, E.A. Intake occasion affects the serum cholesterol lowering of a plant sterol-enriched single-dose yoghurt drink in mildly hypercholesterolaemic subjects. *Eur J Clin Nutr*, 2006;60, 325-33.
  7. Vaishnav, M.M., Jain, P., Jogi, S.R., Gupta, K.R., Coccinoside-K, triterpenoid saponin from *Coccinia indica*. *Orient. J. Chem*. 2001;17, 465–468.
  8. Barua, A.B., Goswami, B.C., Carotenoides of *Cephalandra indica* (*Coccinia indica*). *Curr. Sci*. 1979;48, 630–632.
  9. Vaishnav, M.M., Gupta, K.R., Ombuin 3-O-arabinofuranoside from *Coccinia indica*. *Fitoterapia* 1996;67, 80.
  10. Qudrat-i-Khuda, M., Khaleque, K.A., Miah, M.A.W., Chemical investigations of *Cephalandra indica*. I. Constituents of dry aerial parts. *Sci. Res. (Dacca)* 1965;2, 27–31.
  11. Siddiqui, I.A., Osman, S.M., Subbaram, M.R., Achaya, K.T., Fatty acid components of seed fats from four plant families. *J. Oil Technol. Assoc. India* 1973;5, 8–9.
  12. Azad Khan, A.K., Akhtar, S. & Mahtab, H. *Coccinia indica* in the treatment of patients with diabetes mellitus. *Bangladesh Med Res Counc Bull*, 1979;5, 60-6.
  13. Kumar, G.P., Sudheesh, S. & Vijayalakshmi, N.R. Hypoglycaemic effect of *Coccinia indica*: mechanism of action. *Planta Med*, 1993;59, 330-2.
  14. Hossain, M.Z., B.A. Shibib & R. Rahman, Hypoglycemic effects of *Coccinia indica*: inhibition of key gluconeogenic enzyme, glucose-6-phosphatase. *Indian journal of experimental biology*. 1992;30(5):418-20.
  15. Overtuff, M.L., Loose, M.D.C., In vivo model system: the choice of the experimental model for the analysis of lipoproteins and atherosclerosis. *Curr. Opin. Lipidol*. 1992;3, 179.
  16. Owens, D.R., Luzio, S.D., Coates, P.A., Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in UK. *Diabetic Med*. 13 (9 Suppl 6), 1996; S19–S24.
  17. Hossain, M. Z., Shibib, B. A. & Rahman, R. Hypoglycemic effects of *Coccinia indica*: inhibition of key gluconeogenic enzyme, glucose-6-phosphatase. *Indian J Exp Biol*, 1992; 30, 418-20.
  18. J.B.Harborne (eds.). *Phytochemical Methods: A guide to modern techniques of plant analysis*. 3<sup>rd</sup> ed. Chapman and Hall, London ISBN: 0341235727032, (1998); 302.
  19. S.Sazada, A.Verma, A.A.Rather, F.Jabeen and M.K. Meghvansi. Preliminary phytochemicals analysis of some important medicinal and aromatic plants. *Adv. in Biol. Res.*, 2009; 3, 1883195.
  20. Singh, G.P., Gupta, P. Rawat, A. Puri, Bhatia G. & Maurya, R. Antidyslipidemic activity of polyprenol from *Coccinia grandis* in high-fat diet-fed hamster model. *Phytomedicine: international journal of phytotherapy and phytopharmacology*. 2007;14(12):792-8.
  21. Krishnakumari, S., P. Bhuvanewari & P. Rajeswari, Ameliorative potential of *Coccinia grandis* extract on serum and liver marker enzymes and lipid profile in streptozotocin induced diabetic rats. *Ancient science of life*. 2011;31(1):26-30.